Regentis Biomaterials Ltd. (New York Stock Exchange Arca:RGNT)
| Market Cap | $8.71M-83.5% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 7.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,163 |
| Open | $1.24 |
| Previous Close | $1.25 |
| Day's Range | $1.24 - $1.25 |
| 52-Week Range | $1.16 - $15.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About RGNT
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
$RGNT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RGNT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RGNT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RGNT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RGNT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RGNT from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from RGNT’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
No Form 4 filings in the last 90 days.